In comparison with the control (no cancer) brains, breast cancer-bearing mice treated with vehicle (Py230-Veh), non-cancer mice treated with chemotherapy (ADR-CYP group), and breast cancer mice treated with ADR-CYP (Py230 ​+ ​ADR-CYP) had about 13 ​%, 20 ​%, and 43 ​% reduction respectively in the DNM1 immunoreactivity in the CA1 region (P ​< ​0.04, 0.001, and 0.0001, respectively, Fig. 3A). Here, DNM1 is linked to breast carcinoma.